Pathways linking aging and atheroprotection in Mif-deficient atherosclerotic mice.
MIF
aging
artery tertiary lymphoid organ
atherosclerosis
atypical chemokines
chemokines
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
30
11
2022
received:
13
01
2022
accepted:
21
12
2022
entrez:
16
2
2023
pubmed:
17
2
2023
medline:
18
2
2023
Statut:
ppublish
Résumé
Atherosclerosis is a chronic inflammatory condition of our arteries and the main underlying pathology of myocardial infarction and stroke. The pathogenesis is age-dependent, but the links between disease progression, age, and atherogenic cytokines and chemokines are incompletely understood. Here, we studied the chemokine-like inflammatory cytokine macrophage migration inhibitory factor (MIF) in atherogenic Apoe
Identifiants
pubmed: 36794636
doi: 10.1096/fj.202200056R
doi:
Substances chimiques
Macrophage Migration-Inhibitory Factors
0
Chemokines
0
Apolipoproteins E
0
Trem2 protein, mouse
0
Membrane Glycoproteins
0
Receptors, Immunologic
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e22752Informations de copyright
© 2023 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.
Références
Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141:e139-e596.
Joseph P, Leong D, McKee M, et al. Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. Circ Res. 2017;121:677-694.
Noels H, Weber C, Koenen RR. Chemokines as therapeutic targets in cardiovascular disease. Arterioscler Thromb Vasc Biol. 2019;39:583-592.
Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17:1410-1422.
Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204-212.
Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
Kapurniotu A, Gokce O, Bernhagen J. The multitasking potential of alarmins and atypical chemokines. Front Med (Lausanne). 2019;6:3.
Burger-Kentischer A, Goebel H, Seiler R, et al. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation. 2002;105:1561-1566.
Sinitski D, Kontos C, Krammer C, Asare Y, Kapurniotu A, Bernhagen J. Macrophage migration inhibitory factor (MIF)-based therapeutic concepts in atherosclerosis and inflammation. Thromb Haemost. 2019;119:553-566.
Zernecke A, Bernhagen J, Weber C. Macrophage migration inhibitory factor in cardiovascular disease. Circulation. 2008;117:1594-1602.
Müller II, Müller KAL, Schönleber H, et al. Macrophage migration inhibitory factor is enhanced in acute coronary syndromes and is associated with the inflammatory response. PLoS ONE. 2012;7:e38376.
Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3:791-800.
Tillmann S, Bernhagen J, Noels H. Arrest functions of the MIF ligand/receptor axes in atherogenesis. Front Immunol. 2013;4:115.
Adamali H, Armstrong ME, McLaughlin AM, et al. Macrophage migration inhibitory factor enzymatic activity, lung inflammation, and cystic fibrosis. Am J Respir Crit Care Med. 2012;186:162-169.
Baugh JA, Chitnis S, Donnelly SC, et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun. 2002;3:170-176.
Lefebvre JS, Maue AC, Eaton SM, Lanthier PA, Tighe M, Haynes L. The aged microenvironment contributes to the age-related functional defects of CD4 T cells in mice. Aging Cell. 2012;11:732-740.
Wirtz TH, Tillmann S, Strussmann T, et al. Platelet-derived MIF: a novel platelet chemokine with distinct recruitment properties. Atherosclerosis. 2015;239:1-10.
Bernhagen J, Krohn R, Lue H, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007;13:587-596.
Asare Y, Schmitt M, Bernhagen J. The vascular biology of macrophage migration inhibitory factor (MIF). Expression and effects in inflammation, atherogenesis and angiogenesis. Thromb Haemost. 2013;109:391-398.
Schober A, Bernhagen J, Thiele M, et al. Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation. 2004;109:380-385.
Pan JH, Sukhova GK, Yang JT, et al. Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 2004;109:3149-3153.
Burger-Kentischer A, Gobel H, Kleemann R, et al. Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor (MIF). Atherosclerosis. 2006;184:28-38.
Schmitz C, Noels H, El Bounkari O, et al. Mif-deficiency favors an atheroprotective autoantibody phenotype in atherosclerosis. FASEB J. 2018;32:4428-4443.
Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb Vasc Biol. 1994;14:133-140.
Fox J, Barthold S, Davisson M, Newcomer C, Quimby F, Smith A. The Mouse in Biomedical Research. Elsevier; 2007.
Liberale L, Montecucco F, Tardif JC, Libby P, Camici GG. Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease. Eur Heart J. 2020;41:2974-2982.
Mohanta SK, Yin C, Peng L, et al. Artery tertiary lymphoid organs contribute to innate and adaptive immune responses in advanced mouse atherosclerosis. Circ Res. 2014;114:1772-1787.
Yin C, Mohanta SK, Srikakulapu P, Weber C, Habenicht AJ. Artery tertiary lymphoid organs: powerhouses of atherosclerosis immunity. Front Immunol. 2016;7:387.
Mohanta SK, Peng L, Li Y, et al. Neuroimmune cardiovascular interfaces control atherosclerosis. Nature. 2022;605:152-159.
Akhavanpoor M, Gleissner CA, Akhavanpoor H, et al. Adventitial tertiary lymphoid organ classification in human atherosclerosis. Cardiovasc Pathol. 2018;32:8-14.
Fingerle-Rowson G, Petrenko O, Metz CN, et al. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci U S A. 2003;100:9354-9359.
Asare Y, Ommer M, Azombo FA, et al. Inhibition of atherogenesis by the COP9 signalosome subunit 5 in vivo. Proc Natl Acad Sci U S A. 2017;114:E2766-E2775.
Schlepckow K, Monroe KM, Kleinberger G, et al. Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol Med. 2020;12:e11227.
Picelli S, Bjorklund AK, Faridani OR, Sagasser S, Winberg G, Sandberg R. Smart-seq2 for sensitive full-length transcriptome profiling in single cells. Nat Methods. 2013;10:1096-1098.
Safaiyan S, Besson-Girard S, Kaya T, et al. White matter aging drives microglial diversity. Neuron. 2021;109:1100-1117.e1110.
Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15-21.
Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics. 2002;18(suppl 1):S96-S104.
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
Chen Z, Sakuma M, Zago AC, et al. Evidence for a role of macrophage migration inhibitory factor in vascular disease. Arterioscler Thromb Vasc Biol. 2004;24:709-714.
Ma H, Wang J, Thomas DP, et al. Impaired macrophage migration inhibitory factor-AMP-activated protein kinase activation and ischemic recovery in the senescent heart. Circulation. 2010;122:282-292.
Cochain C, Vafadarnejad E, Arampatzi P, et al. Single-cell RNA-seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis. Circ Res. 2018;122:1661-1674.
Willemsen L, de Winther MP. Macrophage subsets in atherosclerosis as defined by single-cell technologies. J Pathol. 2020;250:705-714.
Kim K, Shim D, Lee JS, et al. Transcriptome analysis reveals nonfoamy rather than foamy plaque macrophages are proinflammatory in atherosclerotic murine models. Circ Res. 2018;123:1127-1142.
Yang H, Galea A, Sytnyk V, Crossley M. Controlling the size of lipid droplets: lipid and protein factors. Curr Opin Cell Biol. 2012;24:509-516.
Buers I, Hofnagel O, Ruebel A, Severs NJ, Robenek H. Lipid droplet associated proteins: an emerging role in atherogenesis. Histol Histopathol. 2011;26:631-642.
Liu SL, Li YH, Shi GY, Jiang MJ, Chang JH, Wu HL. The effect of statin on the aortic gene expression profiling. Int J Cardiol. 2007;114:71-77.
Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763-777.
Wu J, Wang C, Li S, et al. Thyroid hormone-responsive SPOT 14 homolog promotes hepatic lipogenesis, and its expression is regulated by liver X receptor alpha through a sterol regulatory element-binding protein 1c-dependent mechanism in mice. Hepatology. 2013;58:617-628.
Domschke G, Linden F, Pawig L, et al. Systematic RNA-interference in primary human monocyte-derived macrophages: a high-throughput platform to study foam cell formation. Sci Rep. 2018;8:10516.
Brown MS, Kovanen PT, Goldstein JL. Regulation of plasma cholesterol by lipoprotein receptors. Science. 1981;212:628-635.
Sokeechand BSH, Trigatti BL. Un-JAMming atherosclerotic arteries: JAM-L as a target to attenuate plaque development. Clin Sci (Lond). 2019;133:1581-1585.
Steffensen LB, Rasmussen LM. A role for collagen type IV in cardiovascular disease? Am J Physiol Heart Circ Physiol. 2018;315:H610-H625.
Atsumi T, Singh R, Sabharwal L, et al. Inflammation amplifier, a new paradigm in cancer biology. Cancer Res. 2014;74:8-14.
Lelios I, Cansever D, Utz SG, Mildenberger W, Stifter SA, Greter M. Emerging roles of IL-34 in health and disease. J Exp Med. 2020;217:e20190290.
Campbell KA, Lipinski MJ, Doran AC, Skaflen MD, Fuster V, McNamara CA. Lymphocytes and the adventitial immune response in atherosclerosis. Circ Res. 2012;110:889-900.
Hu D, Mohanta SK, Yin C, et al. Artery tertiary lymphoid organs control aorta immunity and protect against atherosclerosis via vascular smooth muscle cell lymphotoxin beta receptors. Immunity. 2015;42:1100-1115.
Srikakulapu P, Hu D, Yin C, et al. Artery tertiary lymphoid organs control multilayered territorialized atherosclerosis B-cell responses in aged ApoE−/− mice. Arterioscler Thromb Vasc Biol. 2016;36:1174-1185.
Tsiantoulas D, Diehl CJ, Witztum JL, Binder CJ. B cells and humoral immunity in atherosclerosis. Circ Res. 2014;114:1743-1756.
Tyrrell DJ, Goldstein DR. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6. Nat Rev Cardiol. 2021;18:58-68.
Liu D, Richardson G, Benli FM, et al. Inflammageing in the cardiovascular system: mechanisms, emerging targets, and novel therapeutic strategies. Clin Sci (Lond). 2020;134:2243-2262.
Smykiewicz P, Segiet A, Keag M, Zera T. Proinflammatory cytokines and ageing of the cardiovascular-renal system. Mech Ageing Dev. 2018;175:35-45.
Rammos C, Hendgen-Cotta UB, Pohl J, et al. Modulation of circulating macrophage migration inhibitory factor in the elderly. Biomed Res Int 2014;2014:582586.
Rammos C, Hendgen-Cotta UB, Deenen R, et al. Age-related vascular gene expression profiling in mice. Mech Ageing Dev. 2014;135:15-23.
Zhao X, Gao M, He J, et al. Perilipin1 deficiency in whole body or bone marrow-derived cells attenuates lesions in atherosclerosis-prone mice. PLoS ONE. 2015;10:e0123738.
Trott DW, Henson GD, Ho MHT, Allison SA, Lesniewski LA, Donato AJ. Age-related arterial immune cell infiltration in mice is attenuated by caloric restriction or voluntary exercise. Exp Gerontol. 2018;109:99-107.
Trott DW, Fadel PJ. Inflammation as a mediator of arterial ageing. Exp Physiol. 2019;104:1455-1471.
Du W, Wong C, Song Y, et al. Age-associated vascular inflammation promotes monocytosis during atherogenesis. Aging Cell. 2016;15:766-777.
Eleftheriadis T, Antoniadi G, Liakopoulos V, et al. Perilipin-1 in hemodialyzed patients: association with history of coronary heart disease and lipid profile. Ther Apher Dial. 2012;16:355-360.
Fan Q, Yan X, Zhang H, et al. IL-34 is associated with the presence and severity of renal dysfunction and coronary artery disease in patients with heart failure. Sci Rep. 2016;6:39324.
Liu Q, Fan J, Bai J, et al. IL-34 promotes foam cell formation by enhancing CD36 expression through p38 MAPK pathway. Sci Rep. 2018;8:17347.
Mitchell RA, Liao H, Chesney J, et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci U S A. 2002;99:345-350.
Aw D, Hilliard L, Nishikawa Y, Cadman ET, Lawrence RA, Palmer DB. Disorganization of the splenic microanatomy in ageing mice. Immunology. 2016;148:92-101.
Masters AR, Jellison ER, Puddington L, Khanna KM, Haynes L. Attrition of T cell zone fibroblastic reticular cell number and function in aged spleens. ImmunoHorizons. 2018;2:155-163.
Saigusa R, Winkels H, Ley K. T cell subsets and functions in atherosclerosis. Nat Rev Cardiol. 2020;17:387-401.
Larbi A, Dupuis G, Khalil A, Douziech N, Fortin C, Fulop T Jr. Differential role of lipid rafts in the functions of CD4+ and CD8+ human T lymphocytes with aging. Cell Signal. 2006;18:1017-1030.
Bazioti V, La Rose AM, Maassen S, et al. T cell cholesterol efflux suppresses apoptosis and senescence and increases atherosclerosis in middle aged mice. Nat Commun. 2022;13:3799.
Tomsig JL, Creutz CE. Copines: a ubiquitous family of Ca(2+)-dependent phospholipid-binding proteins. Cell Mol Life Sci. 2002;59:1467-1477.
Toubal A, Nel I, Lotersztajn S, Lehuen A. Mucosal-associated invariant T cells and disease. Nat Rev Immunol. 2019;19:643-657.
Novikova OA, Nazarkina ZK, Cherepanova AV, et al. Isolation, culturing and gene expression profiling of inner mass cells from stable and vulnerable carotid atherosclerotic plaques. PLoS ONE. 2019;14:e0218892.
Allahverdian S, Chaabane C, Boukais K, Francis GA, Bochaton-Piallat ML. Smooth muscle cell fate and plasticity in atherosclerosis. Cardiovasc Res. 2018;114:540-550.
Fan Y, Zhang J, Chen CY, et al. Macrophage migration inhibitory factor triggers vascular smooth muscle cell dedifferentiation by a p68-serum response factor axis. Cardiovasc Res. 2017;113:519-530.
Moos MP, John N, Grabner R, et al. The lamina adventitia is the major site of immune cell accumulation in standard chow-fed apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25:2386-2391.
Stranford S, Ruddle NH. Follicular dendritic cells, conduits, lymphatic vessels, and high endothelial venules in tertiary lymphoid organs: parallels with lymph node stroma. Front Immunol. 2012;3:350.
Kyaw T, Tay C, Krishnamurthi S, et al. B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ Res. 2011;109:830-840.
Rosenfeld SM, Perry HM, Gonen A, et al. B-1b cells secrete atheroprotective IgM and attenuate atherosclerosis. Circ Res. 2015;117:e28-e39.
Nosalski R, Guzik TJ. Perivascular adipose tissue inflammation in vascular disease. Brit J Pharmacol. 2017;174:3496-3513.
Ahmadieh S, Kim HW, Weintraub NL. Potential role of perivascular adipose tissue in modulating atherosclerosis. Clin Sci (Lond). 2020;134:3-13.
Camino T, Lago-Baameiro N, Sueiro A, et al. Brown adipose tissue sheds extracellular vesicles that carry potential biomarkers of metabolic and thermogenesis activity which are affected by high fat diet intervention. Int J Mol Sci. 2022;23:10826.
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-1131.
Krammer C, Kontos C, Dewor M, et al. A MIF-derived cyclopeptide that inhibits MIF binding and atherogenic signaling via the chemokine receptor CXCR2. Chembiochem. 2021;22:1012-1019.
Kontos C, El Bounkari O, Krammer C, et al. Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting. Nat Commun. 2020;11:5981.
Merk M, Zierow S, Leng L, et al. The d-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF). Proc Natl Acad Sci U S A. 2011;108:E577-E585.
Kim BS, Tilstam PV, Arnke K, et al. Differential regulation of macrophage activation by the MIF cytokine superfamily members MIF and MIF-2 in adipose tissue during endotoxemia. FASEB J. 2020;34:4219-4233.
El Bounkari O, Zan C, Wagner J, et al. MIF-2/D-DT is an atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesis. bioRxiv. 2021. doi:10.1101/2021.12.28.474328